Recombinant Human IL -24
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | IL-24 is a secreted glycoprotein belonging to the IL-10 structural family of cytokines. It is produced by a variety of cell types, including B cells, CD4+ cells, NK cells, lymph node DCs, monocytes, and melanoma cells. IL-24 can signal through the IL20R1/IL20R2 and IL22R1/IL20R2 receptors to initiate a signaling cascade which includes the induction of JAK1/STAT3 phosphorylation. IL-24 is, functionally, a pleiotropic protein but is generally characterized as an anti-cancer cytokine that can selectively inhibit growth of a wide variety of human cancer cells through activities that include the induction of differentiation and apoptosis, and the suppression of angiogenesis and cell proliferation. Recombinant human IL-24 is an 18.9 kDa glycoprotein, containing 161 amino acid residues, including a C-terminal His-tag. |
---|---|
BiologicalActivity | Testing in progress. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human IL -24 is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.